New advances in endocrine hypertension: from genes to biomarkers
Kidney International · 2023-03 · 103 (3) · 485-500
DOI: 10.1016/j.kint.2022.12.021 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Kidney International, 2023-03. Verfasst von Fabio L Fernandes-Rosa und 7 weiteren Autor:innen. Beteiligte Einrichtung: Université Paris Cité, PARCC, Inserm, Paris, France. Electronic address: fabio.fernandes-rosa@inserm.fr. Hauptthemen laut MEDLINE: Hyperaldosteronism, Hypertension, Adrenal Gland Neoplasms. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 174 Literaturangaben. Gefördert von: Agence Nationale de la Recherche, Institut National de la Santé et de la Recherche Médicale, Fondation pour la Recherche Médicale.
Abstract (Originalsprache)
Hypertension (HT) is a major cardiovascular risk factor that affects 10% to 40% of the general population in an age-dependent manner. Detection of secondary forms of HT is particularly important because it allows the targeted management of the underlying disease. Among hypertensive patients, the prevalence of endocrine HT reaches up to 10%. Adrenal diseases are the most frequent cause of endocrine HT and are associated with excess production of mineralocorticoids (mainly primary aldosteronism), glucocorticoids (Cushing syndrome), and catecholamines (pheochromocytoma). In addition, a few rare diseases directly affecting the action of mineralocorticoids and glucocorticoids in the kidney also lead to endocrine HT. Over the past years, genomic and genetic studies have allowed improving our knowledge on the molecular mechanisms of endocrine HT. Those discoveries have opened new opportunities to transfer knowledge to clinical practice for better diagnosis and specific treatment of affected subjects. In this review, we describe the physiology of adrenal hormone biosynthesis and action, the clinical and biochemical characteristics of different forms of endocrine HT, and their underlying genetic defects. We discuss the impact of these discoveries on diagnosis and management of patients, as well as new perspectives related to the use of new biomarkers for improved patient care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Université Paris Cité, PARCC, Inserm, Paris, France. Electronic address: fabio.fernandes-rosa@inserm.fr.
- Université Paris Cité, PARCC, Inserm, Paris, France. Electronic address: sheerazed.boulkroun@inserm.fr.
- Université Paris Cité, PARCC, Inserm, Paris, France.
- Université Paris Cité, PARCC, Inserm, Paris, France; Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Service de Génétique, Paris, France.
- Université Paris Cité, PARCC, Inserm, Paris, France; Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Service de Physiologie, Paris, France.
- Université Paris Cité, PARCC, Inserm, Paris, France; Université de Paris Cité, PARCC, Inserm, Equipe Labellisée par la Ligue contre le Cancer, Paris, France.
Förderung
- Agence Nationale de la Recherche
- Institut National de la Santé et de la Recherche Médicale
- Fondation pour la Recherche Médicale
Zitieren
APA
Fernandes-Rosa, F. L., Boulkroun, S., Fedlaoui, B., Hureaux, M., Travers-Allard, S., Drossart, T., Favier, J., & Zennaro, M. C. (2023). New advances in endocrine hypertension: from genes to biomarkers. Kidney International, 103(3), 485-500. https://doi.org/10.1016/j.kint.2022.12.021
Vancouver
Fernandes-Rosa FL, Boulkroun S, Fedlaoui B, Hureaux M, Travers-Allard S, Drossart T, et al. New advances in endocrine hypertension: from genes to biomarkers. Kidney International. 2023;103(3):485-500. doi:10.1016/j.kint.2022.12.021
BibTeX
@article{FernandesRosa2023,
author = {Fernandes-Rosa, Fabio L and Boulkroun, Sheerazed and Fedlaoui, Bakhta and Hureaux, Marguerite and Travers-Allard, Simon and Drossart, Tom and Favier, Judith and Zennaro, Maria-Christina},
title = {New advances in endocrine hypertension: from genes to biomarkers},
journal = {Kidney International},
year = {2023},
volume = {103},
number = {3},
pages = {485--500},
doi = {10.1016/j.kint.2022.12.021}
}
EUVIMED